anti-FVIII antibody product blog
Tags: Antibody; Polyclonal Antibody; anti-FVIII antibody; FVIII; Factor VIII:C;
The FVIII n/a (Catalog #MBS512051) is an Antibody produced from Sheep and is intended for research purposes only. The product is available for immediate purchase.Suitable as a source of antibodies to Factor VIII. Researchers should empirically determine the suitability of the FVIII n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The FVIII n/a product has the following accession number(s) (GI #4262857) (NCBI Accession #AAD15005.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of F.VIII ranging in size from 200-280 kDa. The F.VIII is stabilized by association with von Willebrand Factor to form a F.VIII-vWF complex required for the normal survival of F.VIII in vivo (t1/2 of 8-12 hours). F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, F.VIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay. Hemophilia An is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of F.VIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a F.VIII protein that is partially or totally inactive. The production of neutralizing antibodies to F.VIII also occurs in 5-20% of Hemophiliacs 1-3.
Immunogen: Human F.VIII (F.VIII:C) purified from concentrate. Buffer: 10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.
Neutralizing Activity: XXXX Bethesda Units/ml IgG against normal plasma (Kasper CK et al, Thromb Diath Haemorrh 34:869, 1975). One Bethesda unit/ml is defined as the amount of inhibitor that resulted in 50% residual F.VIII activity after 2 hours at 37 degree C. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing FVIII are readily searchable from our website. Different antibodies against the same target such as FVIII may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.